-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HMC0s+e8WLmF2Z3jZmIPPJGkP9Qsj8t0La/oFYArM6Ty5Rkd5Z2yo71C80bo5uSf 1n6/4bUYUvyOM5cfge3U0Q== 0001116502-03-000752.txt : 20030502 0001116502-03-000752.hdr.sgml : 20030502 20030501182224 ACCESSION NUMBER: 0001116502-03-000752 CONFORMED SUBMISSION TYPE: NT 10-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20030131 FILED AS OF DATE: 20030502 EFFECTIVENESS DATE: 20030502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOSPECIFICS TECHNOLOGIES CORP CENTRAL INDEX KEY: 0000875622 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113054851 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19879 FILM NUMBER: 03677874 BUSINESS ADDRESS: STREET 1: 35 WILBUR ST CITY: LYNBROOK STATE: NY ZIP: 11563 BUSINESS PHONE: 5165937000 MAIL ADDRESS: STREET 1: 35 WILBUR STREET CITY: LYNBROOK STATE: NY ZIP: 11563 NT 10-K 1 biospecifics-nt10k.txt NOTIFICATION OF LATE FILING UNITED STATES ---------------------------------- SECURITIES AND EXCHANGE COMMISSION OMB APPROVAL WASHINGTON, D.C. 20549 ---------------------------------- OMB Number: FORM 12b-25 Expires: Estimated average burden hours per response ---------------------------------- NOTIFICATION OF LATE FILING SEC FILE NUMBER ---------------------------------- CUSIP NUMBER ---------------------------------- (Check One): [x] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR For the Period Ended: January 31, 2003 -------------- [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Period Ended:_________________ Read Instruction Before Preparing Form. Please Print or Type. Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: - -------------------------------------------------------------------------------- PART I - REGISTRANT INFORMATION Full Name of Registrant: BioSpecifics Technologies Corp. -------------------------------------------------------- Former Name if Applicable: N/A ------------------------------------------------------ Address of Principal Executive Office (Street and number): 35 Wilbur Street ---------------------- City, State and Zip Code: Lynbrook, New York 11563 ------------------------------------------------------- PART II - RULES 12b-25(b) AND (c) If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate) | (a) The reasons described in reasonable detail in Part III of this | form could not be eliminated without unreasonable effort or | expense; | | (b) The subject annual report, semi-annual report, transition report | on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof, | will be filed on or before the fifteenth calendar day following [X} | the prescribed due date; or the subject quarterly report of | transition report on Form 10-Q, or portion thereof will be filed | on or before the fifth calendar day following the prescribed due | date; and | | (c) The accountant's statement or other exhibit required by Rule | 12b-25(c) has been attached if applicable. PART III - NARRATIVE State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra sheets if needed.) The Company's Annual Report on Form 10-KSB will not be filed within the prescribed time period because of unexpected delays in the preparation of the 10-KSB. PART IV - OTHER INFORMATION Name and telephone number of person to contact in regard to this notification Albert Horcher 516 593-7000 -------------- ----------- ----------------- (Name) (Area Code) (Telephone Number) (1) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). [X] Yes [ ] No (2) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? [X] Yes [ ] No If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. For the year ended January 31, 2002, the Company's net loss was approximately ($257,000). For the year ended January 31, 2003, the Company anticipates a net loss of approximately ($3,000,000). Net sales recorded during the fiscal years ended January 31, 2003 and 2002 were primarily from deliveries of stockpiled enzyme inventory to the Company's US customer. We depleted the stockpiled enzyme inventory available for use by that customer during the second quarter of the fiscal year ended January 31, 2003, and as a result, net sales were negatively impacted during the remainder of the year, and insufficient to cover expenses. 2 BioSpecifics Technologies Corp. ------------------------------------------------------------------------------- (Name of Registrant as Specified in Charter) has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 1, 2003 By: /s/ Albert Horcher ----------------- ----------------------------------- Name: Albert Horcher Title: Secretary, Treasurer, Principal Financial and Chief Accounting Officer -----END PRIVACY-ENHANCED MESSAGE-----